Simplify Logo

Full-Time

Director/Sr Director

Legal

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$227k - $296.5kAnnually

Senior

San Carlos, CA, USA

Category
Legal
Legal & Compliance
Required Skills
Sales
Communications
Requirements
  • Active licensure in good standing with the California Bar or at least one other state bar with eligibility to practice law as a registered in-house counsel
  • Comprehensive knowledge of laws implicated in the sale and promotion of pharmaceutical products
  • Complex contract drafting and negotiations skills
  • Excellent written and verbal communication skills
  • Ability to provide timely, practical, and actionable legal advice
  • High emotional intelligence, capable of collaboratively influencing decision-making through the respectful exchange of competing ideas and perspectives
  • Self-driven to identify and solve complex and challenging problems
Responsibilities
  • Legal advice related to pharmaceutical Sales and Promotion – Provide practical and timely advice, training and solutions regarding compliance with laws related to all aspects of U.S. and ex-U.S. pharmaceutical product sales and promotion, including fraud and abuse; interactions with healthcare professionals and patients; market access, reimbursement and government price reporting; channel distribution; pharmacy services; and data privacy
  • Compliance Policy Development and Training – Develop and implement policies, resources, and training to drive comprehensive, functional knowledge among product teams regarding business conduct in accordance with the law and ethical standards
  • Contract Drafting and Negotiations – Support negotiation of contractual arrangements encompassing a wide array of third parties, including healthcare providers and vendors of services, products and data, to ensure appropriate protection of Corcept’s business opportunities, assets, confidential information and intellectual property

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

7%

2 year growth

29%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.